These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. Hoogkamp-Korstanje JA J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. Crokaert F; Aoun M; Duchateau V; Grenier P; Vandermies A; Klastersky J Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):696-8. PubMed ID: 8894585 [No Abstract] [Full Text] [Related]
8. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551 [TBL] [Abstract][Full Text] [Related]
9. Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin. Barry AL; Fuchs PC Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):168-71. PubMed ID: 2060518 [TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest. Waites K; Brookings E; Nix S; Robinson A; Gray B; Swiatlo E Int J Antimicrob Agents; 1998 Feb; 9(4):215-8. PubMed ID: 9573490 [TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones. Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237 [TBL] [Abstract][Full Text] [Related]
12. Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin. Chaudhry AZ; Knapp CC; Sierra-Madero J; Washington JA Antimicrob Agents Chemother; 1990 Sep; 34(9):1843-5. PubMed ID: 2285304 [TBL] [Abstract][Full Text] [Related]
13. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin. Evans ME Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640 [TBL] [Abstract][Full Text] [Related]
14. Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin. Clark CL; Nagai K; Davies TA; Bozdogan B; Dewasse B; Jacobs MR; Appelbaum PC Clin Microbiol Infect; 2002 Jun; 8(6):373-80. PubMed ID: 12084107 [TBL] [Abstract][Full Text] [Related]
15. SYN987, SYN1193, and SYN1253, new quinolones highly active against gram-positive cocci. Kitzis MD; Goldstein FW; Ishida N; Acar JF J Antimicrob Chemother; 1995 Jul; 36(1):209-13. PubMed ID: 8537267 [TBL] [Abstract][Full Text] [Related]
16. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones. Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789 [TBL] [Abstract][Full Text] [Related]
17. The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. Rubinstein E; Diamantstein L; Yoseph G; Gruzman G; Rubinovitch B; Barzilai A; Keller N Clin Microbiol Infect; 2000 Dec; 6(12):678-81. PubMed ID: 11284929 [No Abstract] [Full Text] [Related]
18. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Beyer R; Pestova E; Millichap JJ; Stosor V; Noskin GA; Peterson LR Antimicrob Agents Chemother; 2000 Mar; 44(3):798-801. PubMed ID: 10681364 [TBL] [Abstract][Full Text] [Related]
19. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Hershberger E; Rybak MJ Antimicrob Agents Chemother; 2000 Mar; 44(3):598-601. PubMed ID: 10681324 [TBL] [Abstract][Full Text] [Related]
20. In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones. Schmitz FJ; Boos M; Mayer S; Köhrer K; Scheuring S; Fluit AC Antimicrob Agents Chemother; 2002 Mar; 46(3):934-5. PubMed ID: 11850293 [No Abstract] [Full Text] [Related] [Next] [New Search]